Skip to main content

Claritas HealthTech Pte. Ltd. to enter the North American market via CAD$5M Licensing Agreement and Reverse Takeover of TSXV listed tech company

Written by Customer Service on . Posted in Mergers And Acquisitions.

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) — Singapore-based Claritas HealthTech Pte. Ltd. (“Claritas”) and Labrador Technologies Inc. (“Labrador”) have entered into an exclusive arm’s length software license purchase agreement dated June 28, 2020.
Pursuant to the terms of the Agreement, Labrador will issue sufficient shares such that the Proposed Transaction will constitute a Reverse Takeover (“RTO”) of Labrador under the policies of the TSX Venture Exchange (the “Exchange” or the “TSXV”). Upon the closing of the Proposed Transaction, it is expected that Labrador will continue to be a Technology Issuer on the TSXV and will be renamed as Claritas HealthTech Inc.“With our iRAD platform successfully tested and continuing to be deployed across Asia, the next natural step is for Claritas to establish a presence in North America on account of the size and requirements of its medical imaging market. The completion of the RTO will allow for the rapid deployment of our technology across North America thereby furthering our mission to enable physicians globally to make more informed diagnostic decisions for the betterment of patients,” commented Devika Dutt, Co-founder and COO of Claritas.Claritas is actively looking for potential takeover candidates in the telemedicine and virtual healthcare sectors, both in the regional and North American markets. Besides the medical image processing and enhancement product iRAD, the company will soon be releasing several AI tools that will help clinicians in rapid and accurate detection of abnormalities.
“Our aim is to become a fully integrated digital health company by providing a platform that serves both the healthcare providers and their patients in a meaningful way. The COVID-19 pandemic has changed how business operates especially when operating in the digital healthcare space. Gaining market share is one of the top priorities, however, our focus is to achieve this while maintaining profitability.”About Claritas HealthTech Pte. Ltd.Claritas is incorporated and headquartered in Singapore. Claritas conducts research and development in the fields of image enhancement, machine vision and artificial intelligence (“AI”) with a focus on medical image processing and AI assisted interpretation. Claritas aims to transform the diagnostics industry with powerful and effective software products created using image enhancement and AI technology enabling doctors and physicians to make accurate diagnosis and improve patient lives.For Media Enquiries
Charlotte Ma
PR Consultant, Elliot & Co.
charlotte@elliotcommunications.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.